Temocapril | CAS#111902-57-9

MedKoo Cat#: 526435 | Name: Temocapril

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Temocapril is a tyrosine kinase inhibitor.

Chemical Structure

Temocapril

CAS#111902-57-9

Theoretical Analysis

MedKoo Cat#: 526435

Name: Temocapril

CAS#: 111902-57-9

Chemical Formula: C23H28N2O5S2

Exact Mass: 476.1440

Molecular Weight: 476.61

Elemental Analysis: Chemical Formula: C23H28N2O5S2 Exact Mass: 476.1440 Molecular Weight: 476.6060 Elemental Analysis: C, 57.96; H, 5.92; N, 5.88; O, 16.78; S, 13.45

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Temocapril

IUPAC/Chemical Name

1,4-Thiazepine-4(5H)-acetic acid, 6-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)tetrahydro-5-oxo-2-(2-thienyl)-, (2S-(2alpha,6beta(R*)))-

InChi Key

FIQOFIRCTOWDOW-WSTRIDTPSA-N

InChi Code

InChI=1S/C23H28N2O5S2/c1-2-30-23(29)17(11-10-16-7-4-3-5-8-16)24-18-15-32-20(19-9-6-12-31-19)13-25(22(18)28)14-21(26)27/h3-9,12,17-18,20,24H,2,10-11,13-15H2,1H3,(H,26,27)/t17?,18-,20-/m0/s1

SMILES Code

O=C(O)CN1C[C@@H](C2=CC=CS2)SC[C@H](NC(C(OCC)=O)CCC3=CC=CC=C3)C1=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 476.61 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Mishima E, Hashimoto J, Akiyama Y, Seiji K, Takase K, Abe T, Ito S. Posterior reversible encephalopathy syndrome treated with renin-angiotensin system blockade. J Neurol Sci. 2015 Aug 15;355(1-2):219-21. doi: 10.1016/j.jns.2015.06.007. PubMed PMID: 26073482. 2: Funahashi Y, Sassa N, Inada-Inoue M, Ando Y, Matsukawa Y, Gotoh M. Acute aortic dissection in a patient receiving multiple tyrosine kinase inhibitors for 5 years. Aktuelle Urol. 2014 Mar;45(2):132-4. doi: 10.1055/s-0033-1363274. PubMed PMID: 24700069. 3: Ohura K, Tasaka K, Hashimoto M, Imai T. Distinct patterns of aging effects on the expression and activity of carboxylesterases in rat liver and intestine. Drug Metab Dispos. 2014 Feb;42(2):264-73. doi: 10.1124/dmd.113.054551. PubMed PMID: 24271336. 4: Ohnishi K, Murase M, Nakano D, Pelisch N, Hitomi H, Kobori H, Morimoto S, Mori H, Masaki T, Ohmori K, Kohno M, Ichihara A, Nishiyama A. Angiotensin-converting enzyme inhibitor does not suppress renal angiotensin II levels in angiotensin I-infused rats. J Pharmacol Sci. 2013;122(2):103-8. PubMed PMID: 23698111; PubMed Central PMCID: PMC3786864. 5: Yamamoto D, Takai S, Akimoto T, Hirahara I, Ito C, Muto S, Kusano E. Matrix metalloproteinase-2 inhibition by temocapril and its important role in peritoneal transport. Clin Exp Pharmacol Physiol. 2012 Oct;39(10):864-8. doi: 10.1111/j.1440-1681.2012.12003.x. PubMed PMID: 23013132. 6: Bahar FG, Ohura K, Ogihara T, Imai T. Species difference of esterase expression and hydrolase activity in plasma. J Pharm Sci. 2012 Oct;101(10):3979-88. doi: 10.1002/jps.23258. PubMed PMID: 22833171. 7: Ohura K, Nozawa T, Murakami K, Imai T. Evaluation of transport mechanism of prodrugs and parent drugs formed by intracellular metabolism in Caco-2 cells with modified carboxylesterase activity: temocapril as a model case. J Pharm Sci. 2011 Sep;100(9):3985-94. doi: 10.1002/jps.22628. PubMed PMID: 21618543. 8: Nozawa T, Imai T. Prediction of human intestinal absorption of the prodrug temocapril by in situ single-pass perfusion using rat intestine with modified hydrolase activity. Drug Metab Dispos. 2011 Jul;39(7):1263-9. doi: 10.1124/dmd.110.037937. PubMed PMID: 21474683. 9: Maruyoshi H, Baba T, Ogata J, Nagata S. [A ten-year follow-up of a 109-year-old woman with myocardial infarction]. Nihon Ronen Igakkai Zasshi. 2011;48(1):78-83. Japanese. PubMed PMID: 21378469. 10: Hobara N, Goda M, Hashikawa N, Jin X, Zamami Y, Takatori S, Kawasaki H. [Role of angiontensin receptors in remodeling perivascular nerves]. Yakugaku Zasshi. 2010 Nov;130(11):1421-5. Review. Japanese. PubMed PMID: 21048398. 11: Sugimoto K, Katsuya T, Kamide K, Fujisawa T, Shimaoka I, Ohishi M, Morishita R, Ogihara T, Rakugi H. Promoter Polymorphism of RGS2 Gene Is Associated with Change of Blood Pressure in Subjects with Antihypertensive Treatment: The Azelnidipine and Temocapril in Hypertensive Patients with Type 2 Diabetes Study. Int J Hypertens. 2010 Aug 24;2010:196307. doi: 10.4061/2010/196307. PubMed PMID: 20981351; PubMed Central PMCID: PMC2958339. 12: Fukami T, Takahashi S, Nakagawa N, Maruichi T, Nakajima M, Yokoi T. In vitro evaluation of inhibitory effects of antidiabetic and antihyperlipidemic drugs on human carboxylesterase activities. Drug Metab Dispos. 2010 Dec;38(12):2173-8. doi: 10.1124/dmd.110.034454. PubMed PMID: 20810539. 13: Ito Y, Nishi S, Imai N, Narita I, Gejyo F, Saito K, Nakagawa Y, Tasaki M, Takahashi K. Two distinct FSGS lesions caused by distinct etiology confirmed in a single patient in pre- and post-transplantation. Clin Transplant. 2010 Jul;24 Suppl 22:54-9. doi: 10.1111/j.1399-0012.2010.01267.x. PubMed PMID: 20590696. 14: Ishikawa T, Tanaka R, Suzuki S, Miyaishi Y, Akagi H, Iino Y, Fukushima R, Yamane Y. The effect of angiotensin-converting enzyme inhibitors of left atrial pressure in dogs with mitral valve regurgitation. J Vet Intern Med. 2010 Mar-Apr;24(2):342-7. doi: 10.1111/j.1939-1676.2009.0455.x. PubMed PMID: 20102507. 15: Vistoli G, Pedretti A, Mazzolari A, Bolchi C, Testa B. Influence of ionization state on the activation of temocapril by hCES1: a molecular-dynamics study. Chem Biodivers. 2009 Nov;6(11):2092-100. doi: 10.1002/cbdv.200900174. PubMed PMID: 19937843. 16: Tomita N, Yamasaki K, Osako MK, Komai N, Shimosato T, Morishita R. Combination therapy based on the angiotensin receptor blocker olmesartan for vascular protection in spontaneously hypertensive rats. Mol Med Rep. 2009 Sep-Oct;2(5):733-8. doi: 10.3892/mmr_00000164. PubMed PMID: 21475893. 17: Kaihara M, Nakamura Y, Sugimoto T, Uchida HA, Norii H, Norii H, Hanayama Y, Makino H. Olmesartan and temocapril prevented the development of hyperglycemia and the deterioration of pancreatic islet morphology in Otsuka-Long-Evans-Tokushima Fatty rats. Acta Med Okayama. 2009 Feb;63(1):35-42. PubMed PMID: 19247421. 18: Katayama S, Kawamori R, Iwamoto Y, Saito I, Kuramoto K; ATTEST Study Group.. In half of hypertensive diabetics, co-administration of a calcium channel blocker and an angiotensin-converting enzyme inhibitor achieved a target blood pressure of <130/80 mmHg: the azelnidipine and temocapril in hypertensive patients with type 2 diabetes (ATTEST) study. Hypertens Res. 2008 Aug;31(8):1499-508. doi: 10.1291/hypres.31.1499. PubMed PMID: 18971523. 19: Kawata T, Daimon M, Hasegawa R, Teramoto K, Toyoda T, Sekine T, Yamamoto K, Uchida D, Himi T, Yoshida K, Komuro I. Effect of angiotensin-converting enzyme inhibitor on serum asymmetric dimethylarginine and coronary circulation in patients with type 2 diabetes mellitus. Int J Cardiol. 2009 Feb 20;132(2):286-8. PubMed PMID: 18083252. 20: Satoda M, Takagi K, Uesugi M, Morishima I, Mukawa H, Tsuboi H, Sone T. Acute myocardial infarction caused by spontaneous postpartum coronary artery dissection. Nat Clin Pract Cardiovasc Med. 2007 Dec;4(12):688-92. PubMed PMID: 18033233.